Five Key Trends Shaping the Future of Pharmaceuticals
The Solvias team shares insights on the evolving landscape in pharmaceuticals.
As one of the largest events for the global pharmaceutical sector, CPHI Frankfurt will showcase the latest advancements in science, technology, and market dynamics. Solvias, a prominent global provider of chemistry, manufacturing, and controls (CMC) analysis, is set to engage with industry leaders and share their perspectives on the trends that will shape the future of medicine.
Morberto Bonalumi, PhD, Director of Business Development at Solvias, expresses, "CPHI presents an incredible opportunity to connect with professionals in person. These interactions yield valuable insights into the industry's evolution and assist us in supporting our partners with quality and reliability. This year's event promises to uncover significant trends that will define the pharmaceutical landscape for years to come."
The Solvias experts anticipate five significant topics to dominate discussions at the upcoming event:
1. AI, Big Data, and Omics in Analytics
Artificial intelligence, machine learning, and big data are increasingly pivotal in pharmaceutical analytics. Coupled with advancements in omics, these technologies are on the brink of transforming drug analysis. Daniel Galbraith, PhD, Chief Scientific Officer, emphasizes the importance of understanding drug impact at the single-cell level, a topic expected to generate considerable discussion at CPHI.
2. Expansion of Mass Spectrometry in GMP Settings
One key trend noted at the event will be the integration of high-resolution mass spectrometry in Good Manufacturing Practice (GMP) environments. Rafael Sande, MSc, Senior Director Operations, Bioanalysis & Characterization, highlights that the increasing demand for multi-attribute methodologies reflects a requirement for parallel monitoring of critical quality attributes. This aspect will be crucial for addressing timelines, cost management, and the complexities of drug developments.
3. CMC Development as a Vital Pathway
The focus on accelerating drug development remains central to discussions at CPHI, with Chemistry, Manufacturing, and Controls (CMC) increasingly seen as a critical pathway. Given the heightened expectations related to product complexity and regulatory standards, robust strategies like Quality by Design have become necessary rather than optional. Andreas Hohenleutner, PhD, Senior Director Operations Drug Product CMC & Characterization, emphasizes the need for effective strategies to secure timely approvals and sustainable market presence.
4. The Rise of Oral GLP-1 Small Molecules
The development of small-molecule oral GLP-1 therapies, particularly those targeting obesity and diabetes, is anticipated to be a highlight at CPHI. With innovators like Eli Lilly poised to lead this market segment, Achim Link, PhD, Field Development Services Manager, notes that developments in this area link closely with Solvias's remarkable competencies in solid-state and impurity analysis, positioning them to provide essential analytical support.
5. Innovations in Drug Delivery and Patient-Centric Design
The innovations in drug delivery systems at CPHI reflect an increasing emphasis on the patient experience. Yannick Baschung, PhD, Associate Director of Drug Product Analysis & GC, explains that advancements in in-silico modeling and inhalation delivery systems are generating discussions that prioritize not just drug stability, but how these therapies effectively engage with patients.
As the pharmaceutical industry navigates these trends, the CPHI 2025 event will serve as a pivotal platform for ideas, innovations, and collaborations. This gathering promises to connect professionals, fostering discussions that could shape future successes within the industry.
About Solvias
With over 25 years of experience as a leader in CMC analytics for the life sciences sector, Solvias employs expert teams that blend scientific knowledge with regulatory proficiency across various modalities, including small molecules and biologics. Their comprehensive analytical solutions address everything from raw material testing to drug product release and stability protocols. Based in Switzerland, Solvias is an exemplary provider, operating globally while adhering to the highest standards of ISO, cGMP, GLP, and FDA guidelines.
Frequently Asked Questions
What is CPHI?
CPHI stands for the Convention on Pharmaceutical Ingredients, which is a significant event for networking and sharing innovations in the pharmaceutical sector.
Why is Solvias participating in CPHI 2025?
Solvias is attending to connect with industry leaders, share insights on emerging trends, and strengthen partnerships within the pharmaceutical community.
What trends will be discussed at CPHI 2025?
Prominent topics include AI's role in analytics, mass spectrometry advancements, the importance of CMC development, innovations in oral GLP-1 molecules, and patient-centered drug delivery systems.
Where is CPHI 2025 located?
This year's CPHI will take place in Frankfurt at the Messe Frankfurt from October 28-30, 2025.
What does Solvias specialize in?
Solvias specializes in CMC analytics, offering comprehensive services spanning from testing and development to final drug product release in life sciences.
